Etoposide in combination with low-dose CAG ( cytarabine , aclarubicin , G-CSF ) for the treatment of relapsed or refractory acute myeloid leukemia : a multicenter , randomized control trial in southwest China .
Etoposide in combination with low-dose CAG ( cytarabine , aclarubicin , G-CSF ) for the treatment of relapsed or refractory acute myeloid leukemia : a multicenter , randomized control trial in southwest China . In a well-controlled multi-center randomized trial in southwestern China, 228 patients with refractory or relapsed AML were received a low-dose CAG regimen either with etoposide (E-CAG) or without etoposide (CAG). The complete remission (CR) rate, overall survival (OS) and toxicity were evaluated. Patients with E-CAG had a higher CR rate (71.1% vs. CAG 50.9%, P=0.0002). The tolerability appeared to be equivalent. Patients with CR who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT) had a higher five-year OS over those without allo-HSCT (73.8% vs. 10.8%, P=0.000). The E-CAG regimen is expected to become a bridge between relapsed or refractory AML and allo-HSCT.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Etoposide in combination with low-dose CAG ( cytarabine , aclarubicin , G-CSF ) for the treatment of relapsed or refractory acute myeloid leukemia : a multicenter , randomized control trial in southwest China . In a well-controlled multi-center randomized trial in southwestern China, 228 patients with refractory or relapsed AML were received a low-dose CAG regimen either with etoposide (E-CAG) or without etoposide (CAG). The complete remission (CR) rate, overall survival (OS) and toxicity were evaluated. Patients with E-CAG had a higher CR rate (71.1% vs. CAG 50.9%, P=0.0002). The tolerability appeared to be equivalent. Patients with CR who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT) had a higher five-year OS over those without allo-HSCT (73.8% vs. 10.8%, P=0.000). The E-CAG regimen is expected to become a bridge between relapsed or refractory AML and allo-HSCT.

            ### Response:
            Etoposide, cytarabine, aclarubicin, G-CSF
            